Literature DB >> 22295996

Cytochrome P450 11A1 bioactivation of a kinase inhibitor in rats: use of radioprofiling, modulation of metabolism, and adrenocortical cell lines to evaluate adrenal toxicity.

Donglu Zhang1, Oliver Flint, Lifei Wang, Ashok Gupta, Richard A Westhouse, Weiping Zhao, Nirmala Raghavan, Janet Caceres-Cortes, Punit Marathe, Guoxiang Shen, Yueping Zhang, Alban Allentoff, Jonathan Josephs, Jinping Gan, Robert Borzilleri, W Griffith Humphreys.   

Abstract

A drug candidate, BMS-A ((N-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-3-fluorophenyl)-1-(4-fluorophenyl) 2-oxo-1,2-dihydropyridine- 3-carboxamide)), was associated with dose- and time-dependent vacuolar degeneration and necrosis of the adrenal cortex following oral administration to rats. Pretreatment with 1-aminobenzotriazole (ABT), a nonspecific P450 inhibitor, ameliorated the toxicity. In vivo and in vitro systems, including adrenal cortex-derived cell lines, were used to study the mechanism responsible for the observed toxicity. Following an oral dose of the C-14 labeled compound, two hydroxylated metabolites of the parent (M2 and M3) were identified as prominent species found only in adrenal glands and testes, two steroidogenic organs. In addition, a high level of radioactivity was covalently bound to adrenal tissue proteins, 40% of which was localized in the mitochondrial fraction. ABT pretreatment reduced localization of radioactivity in the adrenal gland. Low levels of radioactivity bound to proteins were also observed in testes. Both M3 and covalent binding to proteins were found in incubations with mitochondrial fraction isolated from adrenal tissue in the presence of NADPH. In vitro formation of M3 and covalent binding to proteins were not affected by addition of GSH or a CYP11B1/2 inhibitor, metyrapone (MTY), but were inhibited by ketoconazole (KTZ) and a CYP11A1 inhibitor, R-(+)-aminoglutethimide (R-AGT). BMS-A induced apoptosis in a mouse adrenocortical cell line (Y-1) but not in a human cell line (H295R). Metabolite M3 and covalent binding to proteins were also produced in Y-1 and to a lesser extent in H295R cells. The cell toxicity, formation of M3, and covalent binding to proteins were all diminished by R-AGT but not by MTY. These results are consistent with a CYP11A1-mediated bioactivation to generate a reactive species, covalent binding to proteins, and subsequently rat adrenal toxicity. The thorough understanding of the metabolism-dependent adrenal toxicity was useful to evaluate cross-species adrenal toxicity potential of this compound and related analogues.
© 2012 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22295996     DOI: 10.1021/tx200524d

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  7 in total

Review 1.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

2.  Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-08-11       Impact factor: 3.739

3.  Introduction: use of radioactive compounds in drug discovery and development.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-02-10       Impact factor: 3.739

4.  Bactericidal and immunomodulatory properties of magnetic nanoparticles functionalized by 1,4-dihydropyridines.

Authors:  Katarzyna Niemirowicz-Laskowska; Katarzyna Głuszek; Ewelina Piktel; Karlis Pajuste; Bonita Durnaś; Grzegorz Król; Agnieszka Z Wilczewska; Paul A Janmey; Aiva Plotniece; Robert Bucki
Journal:  Int J Nanomedicine       Date:  2018-06-11

Review 5.  Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2014-12-19       Impact factor: 3.739

6.  1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology.

Authors:  Paul R Ortiz de Montellano
Journal:  Med Chem (Los Angeles)       Date:  2018-03-31

Review 7.  Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications.

Authors:  F Peter Guengerich
Journal:  Biomol Ther (Seoul)       Date:  2022-01-01       Impact factor: 4.634

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.